Enhancement of classic Kaposi's sarcoma growth after intralesional injections of desferrioxamine.
We have previously shown that iron may be involved in the pathogenesis of Kaposi's sarcoma (KS) and that the iron chelator desferrioxamine (DFO) inhibits the growth and induces the apoptosis of KS cells in vitro. We treated an 85-year-old man with classic KS with 5 weekly intralesional injections of DFO and observed the opposite effect in vivo. The DFO-treated lesion was characterised by the development of numerous KS papules within the drug diffusion area, whereas no change was noted in untreated or control saline-treated lesions. This suggests that intralesional iron chelators are not indicated in patients with KS.
Simonart
T
T
Department of Dermatology, Erasme University Hospital, Brussels, Belgium. tsimonar@ulb.ac.be
Boelaert
J R
JR
Van Vooren
J P
JP
D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000187:drug effects; D003676:Deferoxamine / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D015552:Injections, Intralesional; D007502:Iron Chelating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*
D007502:Iron Chelating Agents; D003676:Deferoxamine